Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting

Rhea-AI Summary

Jazz Pharmaceuticals (Nasdaq: JAZZ) will present eight abstracts, including four late-breaking posters, on Epidiolex (cannabidiol) at the American Epilepsy Society 2025 meeting (Dec 5–9, 2025) in Atlanta.

Key findings include a 6-month intermediate EpiCom analysis showing reductions in TAND-SQ and ABC subscale scores and caregiver/clinician‑reported behavioral severity after 26 weeks of adjunctive Epidiolex in tuberous sclerosis complex; a Phase 1 PK study finding no pharmacokinetic interaction between Epidiolex and cenobamate; preclinical synergistic PD effects with cenobamate; and multiple real-world analyses reporting reduced polypharmacy, antiseizure‑medication cycling, healthcare resource utilization, and seizure frequency versus external control.

Positive

• EpiCom 6‑month analysis: reductions in TAND‑SQ and ABC subscales
• Phase 1 PK study: no pharmacokinetic interaction between Epidiolex and cenobamate
• Real‑world data: reduced polypharmacy and healthcare resource utilization at 12 months
• Expanded Access post‑hoc: reduced convulsive and total seizure frequency versus external placebo control

Negative

• None.

Key Figures

Epidiolex abstracts 8 abstracts AES 2025 Annual Meeting presentations

Late-breaking abstracts 4 abstracts Subset of Epidiolex presentations at AES 2025

Intermediate analysis 6 months Prespecified EpiCom trial behavioral outcomes analysis

EpiCom treatment duration 26 weeks Adjunctive Epidiolex treatment period before behavioral assessment

Follow-up horizon 12 months Real-world analyses of polypharmacy and healthcare resource utilization

EpiCom trial phase Phase 3b/4 Study of non-seizure outcomes in TSC-associated seizures

PK DDI study phase Phase 1 Bidirectional pharmacokinetic interaction study with cenobamate

Pre-news share price $166.39 Price before AES 2025 Epidiolex data release

Market Reality Check

$166.39 Last Close

Volume Volume 580,882 is below the 20-day average of 1,608,971 ahead of the data presentations. low

Technical Shares at $166.39 are trading above the 200-day moving average of $125.18 and about 9% below the 52-week high of $182.99.

Peers on Argus

Peers in Biotechnology show mixed, modest moves, with names like CORT up 0.95% and TECH down 0.64%, suggesting today’s action in JAZZ is more company-specific than sector-driven.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 02	Oncology trial data	Positive	+0.2%	Announced highly significant Phase 3 Ziihera results to be presented at ASCO GI.
Nov 18	Conference appearance	Neutral	-2.5%	Planned participation in Citi’s 2025 Global Healthcare Conference and webcast.
Nov 17	Pivotal trial win	Positive	+20.6%	Positive top-line Phase 3 HERIZON-GEA-01 results supporting Ziihera combinations.
Nov 11	Clinical data update	Positive	+2.9%	Showcased Modeyso and JZP3507 clinical and translational data at SNO 2025.
Nov 05	Earnings and guidance	Positive	-0.4%	Reported 3Q25 revenue growth and updated 2025 guidance with Modeyso launch contribution.

Pattern Detected

Major positive Phase 3 oncology data drew a strong upside reaction, while conferences and earnings updates have shown mixed or even negative next-day moves.

Recent Company History

Over the last month, Jazz reported 3Q25 results with revenue of $1.126B, driven by Xywav, Epidiolex and the Modeyso launch, but the stock dipped slightly after earnings. Subsequent clinical and data-focused releases, including positive Phase 3 HERIZON-GEA-01 results for Ziihera and Modeyso data at SNO 2025, were followed by reactions ranging from modest gains to a strong +20.57% move. Today’s AES 2025 Epidiolex data update fits the pattern of Jazz regularly highlighting new clinical and real‑world evidence across its portfolio.

Market Pulse Summary

This announcement highlights broad clinical and real‑world evidence for Epidiolex across rare epilepsies, including TSC, LGS and DEEs, with 8 abstracts and a 6‑month EpiCom analysis of behavioral outcomes. In context of earlier positive Ziihera Phase 3 results and growing revenues from Epidiolex, the update underscores Jazz’s epilepsy focus. Investors may watch for longer‑term outcomes, additional real‑world datasets, and how these data support label use and clinical adoption.

Key Terms

tuberous sclerosis complex medical

"patients with tuberous sclerosis complex, suggest improvements in non-seizure outcomes"

Tuberous sclerosis complex is a genetic disorder that causes noncancerous growths to form in multiple organs such as the brain, kidneys, heart and lungs, often leading to seizures, developmental delays and organ problems. Investors watch it because treatments, diagnostics and devices targeting this condition can drive clinical trial activity, regulatory decisions and long-term healthcare costs; think of it like a design flaw in a building blueprint that creates many small structural issues needing medical solutions and funding.

phase 3b/4 medical

"an ongoing Phase 3b/4 study evaluating behavioral and other non-seizure outcomes"

Phase 3b/4 denotes late-stage clinical studies conducted either just before regulatory approval (3b) or after a drug is on the market (phase 4). These studies test safety, long-term effects, new doses or uses, and how the medicine performs in broader, real‑world groups — like trying a finished product in many more homes — and their results can change a drug’s approved uses, sales outlook, or trigger safety actions, so investors watch them for revenue and risk signals.

pharmacokinetic medical

"evaluating bidirectional pharmacokinetic (PK) drug-drug interactions between Epidiolex"

Pharmacokinetic describes how a drug moves through and leaves the body — how it is absorbed, spread to tissues, broken down and excreted — like tracking a package from pickup to delivery and disposal. For investors, these properties determine effective dose, safety risks, how often a medicine must be taken, and how reliably it works, which in turn influence clinical trial success, regulatory approval chances, production complexity and a drug’s commercial value.

pharmacodynamic medical

"a novel synergistic pharmacodynamic interaction between Epidiolex and cenobamate"

Pharmacodynamic describes how a drug acts on the body — the biological effects it produces, how strong those effects are, and how long they last. For investors, pharmacodynamic data show whether a treatment actually works and at what dose, shaping expectations about a drug’s safety, effectiveness, regulatory success and market potential; think of it like testing how well a key turns a lock and whether it reliably opens the door.

expanded access program regulatory

"post-hoc analysis from the Expanded Access Program demonstrates Epidiolex treatment"

A program that allows patients with serious or life‑threatening conditions to receive an experimental drug or therapy before it is fully approved by regulators, when they cannot join clinical trials. Investors care because expanded access can change a treatment’s market perception, create early real‑world safety or demand signals, and affect regulatory timelines and potential revenue — like a pre‑order system that also reveals how the product performs outside controlled testing.

developmental and epileptic encephalopathies medical

"in patients with developmental and epileptic encephalopathies (DEEs) and rare epilepsy"

Developmental and epileptic encephalopathies are a group of severe brain disorders that begin early in life, causing significant challenges with learning, development, and seizures. These conditions can limit a child's ability to grow and function normally, often requiring ongoing medical care. For investors, understanding these disorders highlights areas of medical research and treatment development that could lead to new therapies and market opportunities.

AI-generated analysis. Not financial advice.

New interim results from the EpiCom trial, a prospective evaluation of behavioral outcomes in patients with tuberous sclerosis complex, suggest improvements in non-seizure outcomes

Eight abstracts, including four late-breaking abstracts, underscore Jazz's continued commitment to the epilepsy community and advancing the comprehensive treatment for rare forms of epilepsy

For U.S. media and investors only

DUBLIN, Dec. 5, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that eight abstracts, including four that are late-breaking, will be presented on Epidiolex^® (cannabidiol) at the American Epilepsy Society (AES) 2025 Annual Meeting, being held December 5-9, 2025, in Atlanta, Georgia.  

Notable data include new results from the EpiCom trial, an ongoing Phase 3b/4 study evaluating behavioral and other non-seizure outcomes after initiation of adjunctive Epidiolex treatment in participants with tuberous sclerosis complex (TSC)-associated seizures. Notably, the prespecified 6-month intermediate analysis of EpiCom demonstrated promising reductions in the TSC–Associated Neuropsychiatric Disorders Self-Report Quantified Checklist (TAND-SQ) and Aberrant Behavior Checklist (ABC) subscale scores, as well as in the severity of behavioral problems reported by caregivers and clinicians after 26 weeks of Epidiolex treatment.

"We are proud to share extensive research at AES 2025, including findings from the innovative EpiCom trial which utilized novel endpoints focused on individualized outcomes, including each participant's respective most problematic behavior as identified by caregivers and clinicians to ensure our research addresses the priorities of those we serve," said Jessa Alexander, Ph.D., neuroscience therapeutic area head, global medical and scientific affairs of Jazz Pharmaceuticals. "Data from EpiCom and real-world insights continue to expand our understanding of the complex realities faced by patients living with rare epilepsy disorders while further underscoring Epidiolex's ability to contribute to meaningful, holistic management."   

Additional highlights at AES 2025 include:

• A late-breaking poster featuring results from a Phase 1 clinical study evaluating bidirectional pharmacokinetic (PK) drug-drug interactions between Epidiolex and cenobamate, which did not find PK interactions between cannabidiol and cenobamate parent molecules when concomitantly administered at clinically relevant dosages.
• A late-breaking poster showcasing preclinical data that demonstrates a novel synergistic pharmacodynamic interaction between Epidiolex and cenobamate in effectiveness in the mouse maximal electroshock seizure model of acute generalized seizures.
• Two presentations highlight real-world effectiveness of Epidiolex using data from the U.S. Optum^® Market Clarity Database (an integrated electronic health record and claims database). One late-breaking poster features data that shows Epidiolex initiation in CBD-naïve patients with Dravet Syndrome (DS), LGS or TSC is associated with reduced polypharmacy and healthcare resource utilization (HCRU) at 12 months, with further reductions among early-line Epidiolex initiators. The other poster highlights data that indicates Epidiolex initiation also reduces antiseizure medication cycling at 12 months, as well as decreased polypharmacy and HCRU in both pediatric and adult patients.
• A poster presentation featuring post-hoc analysis from the Expanded Access Program demonstrates Epidiolex treatment is associated with reductions in convulsive and total seizure frequency in patients with developmental and epileptic encephalopathies (DEEs) and rare epilepsy syndromes. The comparative effectiveness analysis confirms the superiority of Epidiolex in reducing seizure frequency from baseline compared to an external placebo control arm.
• A poster presentation highlighting a subgroup analysis of Epidiolex pivotal clinical trial data showing participants with Lennox-Gastaut syndrome (LGS) diagnoses, which are secondary to a genetic DEE, experienced consistent efficacy and safety as compared to the overall LGS pivotal trial populations.
• A late-breaking poster presentation on data from the Epilepsy Learning Healthcare System (ELHS), an Epilepsy Foundation-sponsored initiative, highlights its potential to provide real-world treatment insights beyond clinical trials and claims data.

All AES 2025 abstracts are available online at the following link: aesnet.org/education/annual-meeting/aes-abstract-search.

A full list of Jazz Pharmaceuticals' presentations follows below:

Presentation Title	Presenting Author	Poster Details | Date & Time (ET)
Cannabidiol Efficacy in Patients With Lennox-Gastaut Syndrome With Developmental and Epileptic Encephalopathy-Associated Genetic Variants: A Subgroup Analysis	E Thiele	Poster Number: 1.382 Session Date/Time: Saturday December 6, 12:00-2:00pm
Phase 1, Open-Label, Fixed-Sequence, Bidirectional, Pharmacokinetic Drug-Drug Interaction Study Between Cannabidiol and Cenobamate in Healthy Adult Participants	A Vijan	Poster Number: 1.545 Session Date/Time: Saturday December 6, 12:00-2:00pm
An Assessment of Acute Pharmacodynamic Drug-Drug Interactions Between Cannabidiol and Cenobamate in a Mouse Model of Generalized Tonic Seizures	W Hind	Poster Number: 1.546 Session Date/Time: Saturday December 6, 12:00-2:00pm
A Population Health Study of Patients Prescribed Cannabidiol in the Epilepsy Learning Healthcare System (ELHS) Registry	KM Farrell	Poster Number: 1.549 Session Date/Time: Saturday December 6, 12:00-2:00pm
Effectiveness of Cannabidiol in Patients With Rare Epilepsies Compared to External Placebo Control: A Post-Hoc Analysis From the Expanded Access Program	Y Park	Poster Number: 2.337 Session Date/Time: Sunday December 7, 12:00-2:00pm
Real-World Polypharmacy and Healthcare Resource Utilization After Early-Line Treatment With Cannabidiol for Lennox-Gastaut Syndrome, Dravet Syndrome, and Tuberous Sclerosis Complex	M Navetta	Poster Number: 2.433 Session Date/Time: Sunday December 7, 12:00-2:00pm
Tuberous Sclerosis Complex (TSC)–Associated Neuropsychiatric Disorders (TAND) Outcomes Following Adjunctive Cannabidiol (CBD) Treatment: 6-Month Intermediate Analysis of the EpiCom Trial	J Stevens	Poster Number: 3.351 Session Date/Time: Monday December 8, 12:00-1:45pm
Real-World Effectiveness of Cannabidiol on Antiseizure Medication Cycling, Polypharmacy, and Healthcare Resource Utilization: A US Claims Analysis	A Sillah	Poster Number: 3.368 Session Date/Time: Monday December 8, 12:00-1:45pm

About Tuberous Sclerosis Complex
Tuberous sclerosis complex (TSC) is a rare genetic condition.¹ The condition causes mostly benign tumors to grow in vital organs of the body including the brain, skin, heart, eyes, kidneys and lungs² and is a leading cause of genetic epilepsy.³ People with TSC may experience a variety of seizure types. One of the most common is infantile spasms that typically present in the first year of life; focal (or partial) seizures are also very common.⁴ TSC is associated with an increased risk of autism and intellectual disability⁵ and the severity of the condition can vary widely. In some children the disease is very mild, while others may experience life-threatening complications.⁴ Epilepsy is present in about 85% of patients with TSC and may progress to become intractable to medication.^4,6,7 More than 60% of individuals with TSC do not achieve seizure control⁸ with standard treatments such as antiepileptic drugs, epilepsy surgery, ketogenic diet, or vagus nerve stimulation⁸ compared to 30%-40% of individuals with epilepsy who do not have TSC who are drug resistant.^9,10

About Dravet Syndrome
Dravet syndrome (DS) is a rare genetic condition that appears during the first year of life with frequent fever-related seizures (febrile seizures). Later, other types of seizures typically arise, including myoclonic seizures (involuntary muscle spasms).¹¹ Additionally, status epilepticus, a potentially life-threatening state of continuous seizure activity requiring emergency medical care, may occur. Children with DS typically experience poor development of language and motor skills, hyperactivity and difficulty relating to others.

About Lennox-Gastaut Syndrome
Lennox-Gastaut syndrome (LGS) begins in childhood. It is characterized by multiple types of seizures. People with LGS begin having frequent seizures in early childhood, usually between ages 3 and 5.¹² More than three-quarters of affected individuals have tonic seizures, which cause the muscles to contract uncontrollably. Almost all children with LGS develop learning problems and intellectual disability. Many also have delayed development of motor skills such as sitting and crawling. Most people with LGS require help with usual activities of daily living.

About Epidiolex^®/Epidyolex^® (cannabidiol)
Epidiolex/Epidyolex is a prescription, plant-derived cannabis-based medicine administered as an oral solution which contains highly purified cannabidiol (CBD). Cannabidiol, the active ingredient in Epidiolex, is a cannabinoid that naturally occurs in the Cannabis sativa L. plant. The precise mechanisms by which Epidiolex exerts its anticonvulsant effect in humans are unknown. Epidiolex was approved by the U.S. Food and Drug Administration (FDA) for use in the U.S., the European Commission (EC) for use in Europe, the Medicines and Healthcare products Regulatory Agency (MHRA) for use in Great Britain, the Therapeutic Goods Administration for use in Australia, Swissmedic for use in Switzerland, the Food & Nutrition Services of the Israel Ministry of Health for use in Israel, and the New Zealand Medicines and Medical Devices Safety Authority for use in New Zealand, is an oral solution which contains highly purified cannabidiol (CBD). In the U.S., Epidiolex is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS) or tuberous sclerosis complex (TSC) in patients one year of age and older. Epidiolex has received approval in the European Union under the tradename Epidyolex for adjunctive use in conjunction with clobazam to treat seizures associated with LGS and DS in patients two years and older, and for adjunctive use to treat seizures associated with TSC, in patients two years of age and older. Epidiolex has received Orphan Drug Designation (ODD) from the U.S. FDA for the treatment of seizures associated with LGS, DS, and TSC. Similarly, Epidyolex received ODD from the European Medicines Agency (EMA) for the same indications. Epidiolex is also being studied in additional forms of epilepsy, including the EpiFOS exploratory study (NCT07233239) in focal-onset seizures.

Important Safety Information & Indications

CONTRAINDICATION: HYPERSENSITIVITY

EPIDIOLEX (cannabidiol) oral solution is contraindicated in patients with a history of hypersensitivity to cannabidiol or any ingredients in the product.

WARNINGS & PRECAUTIONS

Hepatic Injury:
EPIDIOLEX can cause dose-related transaminase elevations. Concomitant use of valproate and elevated transaminase levels at baseline increase this risk. Obtain transaminase and bilirubin levels prior to starting treatment, at 1, 3, and 6 months after initiation of treatment, and periodically thereafter, or as clinically indicated. Resolution of transaminase elevations occurred with discontinuation of EPIDIOLEX, reduction of EPIDIOLEX and/or concomitant valproate, or without dose reduction. For patients with elevated transaminase levels, consider dose reduction or discontinuation of EPIDIOLEX or concomitant medications known to affect the liver (e.g., valproate or clobazam). Dose adjustment and slower dose titration is recommended in patients with moderate or severe hepatic impairment. Consider not initiating EPIDIOLEX in patients with evidence of significant liver injury. There have been postmarketing reports of cholestatic or mixed patterns of liver injury. Elevated ammonia levels were reported in some patients with transaminase elevations; most taking concomitant valproate, clobazam, or both. Consider discontinuation or dose adjustment of valproate or clobazam if ammonia is elevated.

Somnolence and Sedation:
EPIDIOLEX can cause somnolence and sedation that generally occurs early in treatment and may diminish over time; these effects occur more commonly in patients using clobazam and may be potentiated by other CNS depressants.

Suicidal Behavior and Ideation:
Antiepileptic drugs (AEDs), including EPIDIOLEX, increase the risk of suicidal thoughts or behavior. Inform patients, caregivers, and families of the risk and advise them to monitor and report any signs of depression, suicidal thoughts or behavior, or unusual changes in mood or behavior. If these symptoms occur, consider if they are related to the AED or the underlying illness.

Withdrawal of Antiepileptic Drugs:
As with most AEDs, EPIDIOLEX should generally be withdrawn gradually because of the risk of increased seizure frequency and status epilepticus.

ADVERSE REACTIONS:
The most common adverse reactions in patients receiving EPIDIOLEX (≥10% and greater than placebo) include transaminase elevations; somnolence; decreased appetite; diarrhea; pyrexia; vomiting; fatigue, malaise, and asthenia; rash; insomnia, sleep disorder and poor-quality sleep; and infections. Hematologic abnormalities were also observed.

PREGNANCY:
EPIDIOLEX should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Encourage women who are taking EPIDIOLEX during pregnancy to enroll in the EPIDIOLEX Pregnancy Surveillance Program and the North American Antiepileptic Drug (NAAED) Pregnancy Registry.

DRUG INTERACTIONS:
Strong inducers of CYP3A4 and CYP2C19 may affect EPIDIOLEX exposure. EPIDIOLEX may affect exposure to CYP2C19 substrates (e.g., clobazam, diazepam, stiripentol), orally administered P-gp substrates, or other substrates (see full Prescribing Information). Consider dose reduction of orally administered everolimus, with appropriate therapeutic drug monitoring, when everolimus is combined with EPIDIOLEX. A lower starting dose of everolimus is recommended when added to EPIDIOLEX therapy. Concomitant use of EPIDIOLEX and valproate increases the incidence of liver enzyme elevations. Pneumonia was observed more frequently with concomitant use of EPIDIOLEX and clobazam. Dosage adjustment of EPIDIOLEX or other concomitant medications may be necessary.

INDICATIONS:
EPIDIOLEX (cannabidiol) oral solution is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients 1 year of age and older.

Please read the EPIDIOLEX full Prescribing Information for additional important information here.

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing potentially life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.

Contacts:

Media:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com 
Ireland +353 1 637 2141
U.S. +1 215 867 4948

Investors:
Jack Spinks
Executive Director, Investor Relations
Jazz Pharmaceuticals plc
investorinfo@jazzpharma.com 
Ireland +353 1 634 3211
U.S. +1 650 496 2717

References:

____________________

1 TSC Alliance. What is TSC? https://www.tscalliance.org/understanding-tsc/what-is-tsc/. Accessed December 2025.

2 National Institute of Neurological Disorders and Stroke. Tuberous Sclerosis Complex. https://www.ninds.nih.gov/health-information/disorders/tuberous-sclerosis-complex. Accessed December 2025.

3 TSC Alliance. An introduction to tuberous sclerosis complex. https://www.tscalliance.org/wp-content/uploads/2023/12/An-introduction-to-TSC-2021.pdf. Accessed December 2025.

4 Kingswood JC, d'Augères GB, Belousova E, et al. TuberOus SClerosis registry to increase disease Awareness (TOSCA) - baseline data on 2093 patients. 2017;12(1):2.

5 de Vries PJ, Belousova E, Benedik MP, et al. TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study. Orphanet J Rare Dis. 2018;13(1):157.

6 Tuberous Sclerosis Alliance. Diagnostic criteria. https://www.tscalliance.org/understanding-tsc/diagnosis-criteria/. Accessed December 2025.

7 Jeong A, Wong M. Systemic disease manifestations associated with epilepsy in tuberous sclerosis complex. Epilepsia. 2016;57(9):1443-1449.

8 Chu-Shore CJ, Major P, Camposano S, Muzykewicz D, Thiele EA. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia. 2010;51(7):1236-1241.

9 Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342(5):314-319.

10 French JA. Refractory epilepsy: clinical overview. Epilepsia. 2007;48 Suppl 1:3-7.

11 Epilepsy Foundation. Dravet Syndrome. https://www.epilepsy.com/what-is-epilepsy/syndromes/dravet-syndrome. Accessed December 2025.

12 National Organization for Rare Disorders, Inc. Lennox-Gastaut Syndrome: Signs & Symptoms. https://rarediseases.org/rare-diseases/lennox-gastaut-syndrome/. Accessed December 2025.

View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-present-extensive-new-data-and-real-world-evidence-highlighting-epidiolex-cannabidiol-outcomes-in-treatment-resistant-epilepsies-at-the-american-epilepsy-society-2025-annual-meeting-302633648.html

SOURCE Jazz Pharmaceuticals plc

FAQ

What did Jazz Pharmaceuticals announce about Epidiolex at AES 2025 (JAZZ) on December 5, 2025?

Jazz will present eight abstracts, including four late‑breaking posters, reporting EpiCom behavioral outcomes, PK and preclinical interaction data with cenobamate, and multiple real‑world effectiveness analyses.

What were the key EpiCom trial results for Epidiolex presented by JAZZ at AES 2025?

The prespecified 6‑month intermediate EpiCom analysis showed reductions in TAND‑SQ and ABC subscale scores and reduced caregiver/clinician‑reported behavioral severity after 26 weeks of adjunctive Epidiolex.

Did the Phase 1 study find drug‑drug interactions between Epidiolex and cenobamate (JAZZ)?

No; the Phase 1 bidirectional PK study did not find pharmacokinetic interactions between cannabidiol and cenobamate at clinically relevant dosages.

What real‑world benefits of Epidiolex were reported in Jazz's AES 2025 presentations?

Real‑world analyses indicated Epidiolex initiation was associated with reduced polypharmacy, less antiseizure‑medication cycling, and lower healthcare resource utilization at 12 months.

Does Jazz report seizure frequency improvement with Epidiolex in rare epilepsies at AES 2025?

Yes; a post‑hoc analysis from the Expanded Access Program reported reductions in convulsive and total seizure frequency and superiority versus an external placebo control.